{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:19:20Z","timestamp":1793848760401,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":2478,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Royal Marsden Palliative Care Research Fund and Asmarley Trust"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.jpainsymman.2012.03.015","type":"journal-article","created":{"date-parts":[[2012,9,18]],"date-time":"2012-09-18T02:30:20Z","timestamp":1347935420000},"page":"670-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Plasma Morphine and Metabolite Concentrations Are Associated With Clinical Effects of Morphine in Cancer Patients"],"prefix":"10.1016","volume":"45","author":[{"given":"Sophy K.","family":"Gretton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy R.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Rutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroe","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Droney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Joel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2012.03.015_bib1","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2001.19.9.2542","article-title":"Strategies to manage the adverse effects of oral morphine: an evidence-based report","volume":"19","author":"Cherny","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib2","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/0024-3205(87)90431-0","article-title":"Morphine-6-glucuronide, a potent mu agonist","volume":"41","author":"Pasternak","year":"1987","journal-title":"Life Sci"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0304-3959(92)90065-J","article-title":"Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat","volume":"48","author":"Gong","year":"1992","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0024-3205(90)90619-3","article-title":"Morphine-3-glucuronide\u2013a potent antagonist of morphine analgesia","volume":"47","author":"Smith","year":"1990","journal-title":"Life Sci"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0304-3959(93)90056-U","article-title":"Lack of effect of morphine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat: an electrophysiological study","volume":"53","author":"Hewett","year":"1993","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1124\/jpet.102.035626","article-title":"Morphine-3beta-D-glucuronide suppresses inhibitory synaptic transmission in rat substantia gelatinosa","volume":"302","author":"Moran","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib7","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/00000542-198605000-00008","article-title":"High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications","volume":"64","author":"Yaksh","year":"1986","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bjp.0705418","article-title":"Different distribution of morphine and morphine-6 beta-glucuronide after intracerebroventricular injection in rats","volume":"140","author":"Okura","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1034\/j.1399-6576.2000.440605.x","article-title":"Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation","volume":"44","author":"Klepstad","year":"2000","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1191\/0269216303pm835oa","article-title":"Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients","volume":"17","author":"Klepstad","year":"2003","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s002280050003","article-title":"Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine","volume":"55","author":"Klepstad","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1191\/0269216303pm658oa","article-title":"Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain","volume":"17","author":"Quigley","year":"2003","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0304-3959(94)00148-8","article-title":"Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients","volume":"61","author":"Tiseo","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0885-3924(95)00148-4","article-title":"Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain","volume":"11","author":"Faura","year":"1996","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib15","first-page":"56","article-title":"No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid","volume":"14","author":"Riley","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.tpj.6500327","article-title":"Clinical response to morphine in cancer patients and genetic variation in candidate genes","volume":"5","author":"Ross","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib17","series-title":"The Royal Marsden Hospital Palliative Care Guidelines 2003","author":"Department of Palliative Medicine","year":"2003"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","article-title":"Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases","volume":"17","author":"Daut","year":"1983","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0378-4347(00)83176-X","article-title":"An improved method for the simultaneous determination of morphine and its principal glucuronide metabolites","volume":"430","author":"Joel","year":"1988","journal-title":"Chromatography"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib20","unstructured":"Cleeland C. The Brief Pain Inventory (short form). 2009. Available from http:\/\/www.mdanderson.org\/education-and-research\/departments-programs-and-labs\/departments-and-divisions\/symptom-research\/symptom-assessment-tools\/brief-pain-inventory.html. Accessed July 5,\u00a02009."},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0885-3924(02)00531-6","article-title":"Relationships among morphine metabolism, pain and side effects during long-term treatment: an update","volume":"25","author":"Andersen","year":"2003","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0163-7258(89)90122-8","article-title":"UDP-glucuronosyltransferases","volume":"43","author":"Burchell","year":"1989","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0304-3959(97)00142-5","article-title":"Systematic review of factors affecting the ratios of morphine and its major metabolites","volume":"74","author":"Faura","year":"1998","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.clpt.2003.08.011","article-title":"Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine","volume":"74","author":"Kharasch","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib25","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","article-title":"Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues","volume":"84","author":"Thiebaut","year":"1987","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pharmthera.2005.06.005","article-title":"Expression and function of efflux drug transporters in the intestine","volume":"109","author":"Takano","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib27","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1046\/j.1471-4159.2003.01990.x","article-title":"Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier","volume":"86","author":"Bourasset","year":"2003","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib28","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/00000542-200412000-00020","article-title":"Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans","volume":"101","author":"Skarke","year":"2004","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib29","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0090-9556(24)11822-3","article-title":"Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat","volume":"27","author":"Letrent","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/sj.bjp.0702804","article-title":"The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-\/-) and mdr1a (+\/+) mice","volume":"128","author":"Xie","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1023\/A:1007546719287","article-title":"Morphine antinociception is enhanced in mdr1a gene-deficient mice","volume":"17","author":"Zong","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2125.2000.00226.x","article-title":"Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine","volume":"50","author":"Drewe","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003088-200241010-00004","article-title":"Drug interactions with patient-controlled analgesia","volume":"41","author":"Lotsch","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0304-3959(97)00044-4","article-title":"Loss of analgesic effect of morphine due to coadministration of rifampin","volume":"72","author":"Fromm","year":"1997","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0885-3924(01)00392-X","article-title":"Increased plasma morphine metabolites in terminally ill cancer patients with delirium: an intra-individual comparison","volume":"23","author":"Morita","year":"2002","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib36","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/sj.bjp.0707257","article-title":"Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux","volume":"151","author":"Groenendaal","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib37","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.lfs.2005.09.043","article-title":"Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronide","volume":"78","author":"Bourasset","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3959(97)00090-0","article-title":"Pathophysiology and treatment of opioid-related myoclonus in cancer patients","volume":"74","author":"Mercadante","year":"1998","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2012.03.015_bib39","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/bmj.299.6692.150","article-title":"Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs","volume":"299","author":"Potter","year":"1989","journal-title":"BMJ"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392412003053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392412003053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:09:28Z","timestamp":1760130568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392412003053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0885392412003053"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.03.015","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma Morphine and Metabolite Concentrations Are Associated With Clinical Effects of Morphine in Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}